MKM.A. Kovaleva

M.A. Kovaleva

*This is an algorithmically generated author record based on publicly available information.

M.A. Kovaleva has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • PREDICTORS OF THE NEED FOR ARTIFICIAL LUNG VENTILATION AFTER MINIMALLY INVASIVE INJECTION OF BERACTANT IN PREMATURE NEWBORNS

    by N.N. Volodin, Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology, A.V. Mostovoi, A.L. Karpova, E.V. Schepkina, A.S. Petrova, S.Yu. Figol, Z.R. Mukhametzyanova, O.B. Bakhmetyeva, T.I. Pavlova, et al.

    The purpose of the study was to predict the ineffectiveness of the first injection of Beractant by a minimally invasive method in the first 6 hours of life and the use of artificial lung ventilation (ALV) in premature newborns with a gestational age (GA) of less than 32 weeks with respiratory distress syndrome (RDS) at the age of 72 hours of life. Materials and methods of the research: a multicenter, retrospective, cohort study was carried out. Nine perinatal centers from different Russia regions took part in the research from July 1, 2019 till June 30, 2020. A total of 102 premature newborns at the GA of less than 32 weeks participated in the survey. The 100 mg/kg Beractant was used in the first and repeated injections of surfactant. The first injection was allowed at the age of not later than 6 hours of life. The authors have studied the methods of injection by a thin catheter represented by the term less invasive surfactant administration (LISA) or through an endotracheal tube using INSURE method, which consists of an intubation-surfactant-extubation sequence. The two comparison groups of patients were formed. Group 1 of 69 children “without ALV”: after the introduction of Beractant the patients had needed non-invasive respiratory support (non-invasive ventilation (NIV) and continuous positive airway pressure (CPAP)). Group 2 of 33 children “with ALV”: needed intubation trachea and invasive ALV during the first 72 hours of life. Results: both groups did not differ statistically significantly in terms of gender, GA, body weight and length at birth, as well as in the APGAR score. The statistically significant differences were found in the duration of the anhydrous interval (Me [Q1; Q3] in children “without ALV” 72.0 [27.0; 95.0] hours versus 15.0 [6.8; 59.2] hours in children “with ALV,” p=0.035) and by the level of C-Reactive Protein (CRP) in the blood: the median (Me) maximum value in children “without ALV” was 8.0 [7.4; 10.0] mg/l versus 19.45 [11.2; 28.7] mg/l in in children “with ALV.” The risk of transfer to ALV in those children who were injected with Beractant using INSURE was 3,625 [1,137; 11,552] times higher than in those who were administered using LISA. Conclusion: the predictors for ALV in the first 72 hours of life in premature newborns with GA of less than 32 weeks are a short anhydrous period and a high level of CRP in the child's blood. The use of the INSURE method in comparison with LISA adds about 3.6 times higher risk of need for the ALV in patients with RDS in the first 72 hours of life (in the selection described in the article).

  • MINIMALLY INVASIVE ADMINISTRATION OF BERACTANT IN PREMATURE INFANTS WITH GESTATIONAL AGE OF LESS THAN 32 WEEKS: RESULTS OF A RETROSPECTIVE COHORT STUDY

    by N.N. Volodin, Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology, A.V. Mostovoi, A.L. Karpova, A.S. Petrova, V.R. Amirova, S.Yu. Figol, T.I. Pavlova, M.A. Kovaleva, Z.R. Mukhametzyanova, et al.

    The aim of the study was to analyze respiratory therapy and the outcomes of nursing preterm infants with gestational age (GA) of less than 32 weeks, who received Beractant in various ways in order to determine the most optimal methods of surfactant administration. Materials and methods of research: a multicenter retrospective cohort study. It was carried out in nine perinatal centers in different regions of the Russian Federation in the period from 07/01/2019 to 06/30/2020. A total of 258 preterm infants with GA of less than 32 weeks participated in the study. One surfactant was used – Beractant (Survant®) at a dose of 100 mg/kg for the first and repeated administration. Beractant was injected by LISA, INSURE or through an endotracheal tube (ETT). Two groups – 1st (154 children) – administration of Beractant via ETT, 2nd (104 children) – minimally invasive surfactant therapy (MIST) of Beractant – combined the LISA and INSURE methods. Two subgroups were identified in the 2nd group: subgroup 2a (27 children) – administration of Beractant by the LISA method, subgroup 2b (77 children) – administration of Beractant by the INSURE method. Results: the ETT and MIST groups were comparable in terms of the median GA (30 versus 30 weeks, p=0.107, respectively) and body weight at birth (1244 versus 1405 g, p=0.067, respectively). In the ETT group in comparison with the MIST group, the administration of Beractant was performed earlier (10 versus 15 min of life, p=0.003, respectively), the need for respiratory support was longer (196.0 versus 120.0 h, p=0.001, respectively), the need for high-frequency oscillatory ventilation was more common (19.7% versus 7.7%, p<0.001, respectively), as well as the need for invasive mechanical ventilation by 72 hours of life (95.4% versus 31.7%, p<0.001, respectively). The incidence of bronchopulmonary dysplasia (BPD) and the length of stay in the intensive care unit and neonatal intensive care unit (NICU) in the ETT group significantly outperformed the MIST group (35.8% versus 13.6%, p<0.001; 10.0 versus 6,0 days, p<0.001, respectively). There were no differences in the frequency of deaths, intraventricular hemorrhages, pneumothoraxes and other complications. The INSURE and LISA subgroups differed in GA and birth weight (30.0 versus 28.0 weeks, p=0.048; 1490.0 versus 1100.0 g, p=0.001, respectively). Conclusions: minimally invasive administration of Beractant significantly reduces the need for invasive respiratory therapy, and, as a result, the incidence of BPD in premature infants with GA of less than 32 weeks.

  • CONGENITAL INFECTION CAUSED BY THE SARS-CоV-2: LITERATURE REVIEW AND FIRST CLINICAL CASE

    by A.L. Karpova, Kaluga Kaluga Oblast Regional Clinical Hospital, M.A. Kovaleva, N.Yu. Karpov, A.V. Mostovoi, I.M. Chelnokova, S.Yu. Kirdyanov, Yaroslavl Yaroslavl Oblast Regional Perinatal Center, Tutayev Tutayev Central District Hospital

    COVID-19 is a disease caused by the novel SARS-CoV-2, is a severe systemic thrombotic syndrome with respiratory tract damage that emerged in 2019 in China with the development of a subsequent pandemic. Over the past two years, very little information has been accumulated on the prevalence, transmission routes, and the clinical picture of the disease among newborn infants. Given the limited data in the domestic literature, authors present not only a description of the first clinical observation of confirmed new coronavirus infection in a premature newborn, but also a brief review of the literature on the description of the epidemiology, clinic and methods of therapy for COVID-19 in infants.


  • MORBIDITY AND PREDICTORS OF LETHAL OUTCOME IN PREMATURE INFANTS WHO RECEIVED PORACTANT ALPHA WITH GESTATION AGE OF LESS THAN 32 WEEKS

    by A.V. Mostovoi, A.L. Karpova, N.R. Kharitonova, O.V. Avdei, M.A. Kovaleva, Yaroslavl Yaroslavl Oblast Regional Perinatal Center, A.S. Petrova, Balashikha Moscow Oblast Regional Perinatal Center, M.V. Kondratyev, I.I. Mebelova, et al.

    The aim of the study – to analyze the morbidity and search for predictors of death in premature infants with a gestational age (GA) of 32 weeks or less, born in perinatal centers and received Poractant alfa (PA) in the treatment of respiratory distress syndrome (RDS), in order to improve the quality of medical care for premature babies. Materials and methods of research: a multicenter prospective open-label non-randomized continuous comparative study was conducted in five perinatal centers from 2020 to 2021. A total of 264 patients, and inclusion criteria: GA less than 32 weeks, the need for PA replacement therapy in the first minutes of life, the first dose of PA – 200 mg/kg, the second dose of PA – 100 mg/kg, strict adherence to the study protocol. Children who did not require PA therapy in the delivery room, who received other types of surfactants, as well as those with congenital malformations, genetic and/or chromosomal abnormalities, early neonatal sepsis, and deviations from the study protocol were excluded. Children were divided into 3 groups: group 1 (200 children) – invasive PA (ETT), group 2 (19 children) – PA injection by INSURE method, group 3 (45 children) – PA injection by LISA method. Results: the median birth weight of all 264 children was 1090.0 g, GA – 28.0 weeks. The median age of the first PA injection is 10.0 [10.0; 10.0] min of life. PA was reintroduced in 20.1% (53/264) of children, invasive mechanical ventilation (IV) was required in 82.6% (218/264) of cases, high-frequency oscillatory mechanical ventilation (HFOV) – in 24.0% (59/264 ). The incidence of bronchopulmonary dysplasia was 37.5% (99/264) of cases and prevailed in the ETT group in comparison with LISA (43.0% versus 27.0%, respectively, p=0.043) and INSURE (43.0% versus 5.0 %, p=0.001). Predictors of death were low gestational age and birth weight, surgical stage of necrotizing enterocolitis, hemodynamically significant patent ductus arteriosus, grade III intraventricular hemorrhage, and pulmonary hemorrhage. The development of the latter in the first 72 hours of life increases the risk of death by 19.7 times. Conclusions: minimally invasive administration of PA by INSURE and LISA methods associated with reduce of morbidity and improves outcomes in premature infants who less than 32 weeks of GA. Pulmonary hemorrhage was the most dangerous among the predictors of death, increasing the risk of death by almost 20 times.


  • EFFECT OF BOVINE AND PORCINE SURFACTANT IN PRETERM NEWBORNS WITH RESPIRATORY DISTRESS SYNDROME ON SHORT-TERM OUTCOMES: A PILOT MULTICENTER STUDY

    by Kaluga Kaluga Oblast Regional Clinical Hospital, A.L. Karpova, A.V. Mostovoi, N.R. Haritonova, N.N. Kondakova, Yaroslavl Yaroslavl Oblast Regional Clinical Hospital Named After N.A. Semashko, M.A. Kovaleva, Yaroslavl Yaroslavl Oblast Regional Perinatal Center, I.I. Mebelova, Petrozavodsk Republic Of Karelia Regional Perinatal Center, et al.

    Облако Mail.ru - это ваше персональное надежное хранилище в интернете.